The Food and Drug Administration approved on Wednesday a drug that could extend the survival of those with metastatic pancreatic cancer.

Rasonque joins a short list of treatment options for one of the country’s deadliest types of cancer.

The therapy is a brand new targeted drug for the disease which experts have labelled as a substantial breakthrough following doubling of survival time in a trial.